Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
4 reports, 3 independent
Updated Mon 00:00
Mostly repetition
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Eli Lilly and Novo Nordisk are facing market share losses in the GLP-1 sector, with trading taking place in Copenhagen's capital market.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector.Also in this story
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.
- New competing products are launching in the weight-loss market, intensifying the competition between Eli Lilly and its rivals.
- Eli Lilly and Novo Nordisk are competing for market share in the weight loss drug sector, seeking Australian regulatory approval.
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- Eli Lilly and Company received full FDA approval, expanded a safety study into India, and broke ground on a new facility in Houston while competing in the GLP-1 market.
- Eli Lilly, Merck, and Novo Nordisk are competing in the GLP-1 economics market, with Novo Nordisk referencing a SUSE cardiovascular trial.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.